Free Trial
NASDAQ:LIPO

Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis

Lipella Pharmaceuticals logo
$2.93 -0.15 (-4.87%)
Closing price 03:57 PM Eastern
Extended Trading
$2.56 -0.38 (-12.80%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lipella Pharmaceuticals Stock (NASDAQ:LIPO)

Key Stats

Today's Range
$2.80
$3.05
50-Day Range
$2.18
$3.08
52-Week Range
$1.97
$12.00
Volume
22,428 shs
Average Volume
721,451 shs
Market Capitalization
$7.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

LIPO MarketRank™: 

Lipella Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Lipella Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lipella Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lipella Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lipella Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.03% of the float of Lipella Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lipella Pharmaceuticals has recently increased by 671.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lipella Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Lipella Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.03% of the float of Lipella Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lipella Pharmaceuticals has recently increased by 671.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lipella Pharmaceuticals has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lipella Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for LIPO on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Lipella Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lipella Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.11% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lipella Pharmaceuticals' insider trading history.
Receive LIPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LIPO Stock News Headlines

Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
See More Headlines

LIPO Stock Analysis - Frequently Asked Questions

Lipella Pharmaceuticals' stock was trading at $3.05 at the beginning of 2025. Since then, LIPO stock has decreased by 3.9% and is now trading at $2.93.
View the best growth stocks for 2025 here
.

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) announced its earnings results on Wednesday, May, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter. The firm had revenue of $0.13 million for the quarter. Lipella Pharmaceuticals had a negative trailing twelve-month return on equity of 192.33% and a negative net margin of 882.82%.

Shares of Lipella Pharmaceuticals reverse split on Friday, November 8th 2024. A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering (IPO) on Tuesday, December 20th 2022. The company issued 1,217,391 shares at a price of $5.75 per share.

Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), MSP Recovery (LIFW), NVIDIA (NVDA), Processa Pharmaceuticals (PCSA), Energy Transfer (ET) and Labor Smart (LTNC).

Company Calendar

Last Earnings
5/14/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LIPO
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,620,000.00
Net Margins
-882.82%
Pretax Margin
-882.61%

Debt

Sales & Book Value

Annual Sales
$536,357.00
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
0.68

Miscellaneous

Free Float
821,000
Market Cap
$7.47 million
Optionable
Not Optionable
Beta
0.26
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:LIPO) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners